McCoyRG, Van HoutenHK, ZiegenfussJY, ShahND, VermersRA, SmithSA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care, 2012; 35: 1897–901.
2.
PickupJC, YemaneN, BrackenridgeA, PenderS. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabet Technol Therapeut, 2014; 16: 1–5.
3.
PickupJC, SuttonAJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med, 2008; 25: 765–74.
4.
RetnakaranR, HochmanJ, DeVriesJH, Hanaire-BroutinH, HeineRJ, MelkiV, ZinmanB. Continuous subcutaneous insulin infusion versus multiple daily injections. The impact of baseline A1c. Diabetes Care, 2004; 27: 2590–96.
5.
National Institute for Health and Clinical Excellence. Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus. Technology Appraisal Guidance 151 (Review of Technology Appraisal Guidance 57). London, England: NICE, 2008.
6.
NixonR, FolwellR, PickupJC. Variations in the quality and sustainability of long-term glycaemic control with continuous subcutaneous insulin infusion. Diabetic Med, 2014; 31: 1174–77.
7.
KordonouriO, PankowskaE, RamiB, KapellenT, CoutantR, HartmannR, LangeK, KnipM, DanneT. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia, 2010; 53: 2487–95.
8.
EdelmanSV. Comment on Little et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2×2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care, 2014; 37: e270–71.
9.
PickupJC. Banting Memorial Lecture 2014. Technology and diabetes care: appropriate and personalized. Diabetic Med, 2015; 32: 3–13.
